Skip to main content

Advertisement

SpringerLink
Log in

Update on hereditary breast cancer

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Women with BRCA1 or BRCA2 mutations are at substantial risk for breast and ovarian cancer. This review describes recent developments in the approach to hereditary breast cancer. Risk-reducing surgeries remain the most effective means of preventing breast cancer in mutation carriers. For women with breast tissue at risk, magnetic resonance imaging is rapidly becoming incorporated into screening programs. For affected women, management does not currently differ from that of women with sporadic breast cancer, although women may choose to undergo bilateral mastectomy. Preclinical data suggest that BRCA mutation-associated breast cancers may benefit from specific targeted therapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Claus EB, Schildkraut JM, Thompson WD, Risch NJ: The genetic attributable risk of breast and ovarian cancer. Cancer 1996, 77:2318–2324.

    Article  PubMed  CAS  Google Scholar 

  2. Ford D, Easton DF, Stratton M, et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676–689.

    Article  PubMed  CAS  Google Scholar 

  3. Struewing JP, Hartge P, Wacholder S, et al.: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997, 336:1401–1408.

    Article  PubMed  CAS  Google Scholar 

  4. Antoniou A, Pharoah PD, Narod S, et al.: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117–1130. This important combined analysis assesses the risks of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.

    Article  PubMed  CAS  Google Scholar 

  5. Phillips KA, Andrulis IL, Goodwin PJ: Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different? J Clin Oncol 1999, 17:3653–3663.

    PubMed  CAS  Google Scholar 

  6. Hartmann LC, Sellers TA, Schaid DJ, et al.: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001, 93:1633–1637.

    Article  PubMed  CAS  Google Scholar 

  7. Meijers-Heijboer H, van Geel B, van Putten WL, et al.: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345:159–164.

    Article  PubMed  CAS  Google Scholar 

  8. Rebbeck TR, Friebel T, Lynch HT, et al.: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004, 22:1055–1062. This important retrospective cohort study confirms the efficacy of bilateral prophylactic mastectomy in breast cancer risk reduction in BRCA mutation carriers.

    Article  PubMed  Google Scholar 

  9. Rebbeck TR, Levin AM, Eisen A, et al.: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999, 91:1475–1479.

    Article  PubMed  CAS  Google Scholar 

  10. Rebbeck TR, Lynch HT, Neuhausen SL, et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346:1616–1622. This important study assesses the efficacy of prophylactic oophorectomy in reducing breast and ovarian cancer risks in BRCA mutation carriers.

    Article  PubMed  Google Scholar 

  11. Kauff ND, Satagopan JM, Robson ME, et al.: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002, 346:1609–1615.

    Article  PubMed  Google Scholar 

  12. Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371–1388.

    Article  PubMed  CAS  Google Scholar 

  13. King MC, Wieand S, Hale K, et al.: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001, 286:2251–2256. This important study describes the lack of benefit of tamoxifen in preventing breast cancer in BRCA mutation carriers in the P1 trial.

    Article  PubMed  CAS  Google Scholar 

  14. Brekelmans CT, Seynaeve C, Bartels CC, et al.: Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001, 19:924–930.

    PubMed  CAS  Google Scholar 

  15. Carney PA, Miglioretti DL, Yankaskas BC, et al.: Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003, 138:168–175.

    PubMed  Google Scholar 

  16. Scheuer L, Kauff N, Robson M, et al.: Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002, 20:1260–1268.

    Article  PubMed  Google Scholar 

  17. Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al.: A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 2002, 102:91–95.

    Article  PubMed  CAS  Google Scholar 

  18. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, et al.: First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 2000, 63:53–60.

    Article  PubMed  CAS  Google Scholar 

  19. Kuhl CK, Schrading S, Leutner CC, et al.: Surveillance of "high risk" women with proven of suspected familial (hereditary) breast cancer: First mid-term results of a multi-modality clinical screening trial [abstract]. http://www.asco.org/ac/1,1003,_12-002640-00_18-0023-00_19-00101944,00.asp. Accessed August 9, 2005.

  20. Kriege M, Brekelmans CT, Boetes C, et al.: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004, 351:427–437.

    Article  PubMed  CAS  Google Scholar 

  21. Warner E, Plewes DB, Hill KA, et al.: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004, 292:1317–1325. This important study addresses the sensitivity, specificity, and positive predictive value of MRI in combination with other modalities for breast cancer screening in BRCA mutation carriers.

    Article  PubMed  CAS  Google Scholar 

  22. Lehman CD, Blume JD, Weatherall P, et al.: Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005, 103:1898–1905.

    Article  PubMed  Google Scholar 

  23. Leach MO, Boggis CR, Dixon AK, et al.: Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005, 365:1769–1778.

    Article  PubMed  CAS  Google Scholar 

  24. Robson ME, Offit K: Breast MRI for women with hereditary cancer risk. JAMA 2004, 292:1368–1370.

    Article  PubMed  CAS  Google Scholar 

  25. Liberman L: Breast cancer screening with MRI: What are the data for patients at high risk? N Engl J Med 2004, 351:497–500.

    Article  PubMed  CAS  Google Scholar 

  26. Warner E, Causer PA: MRI surveillance for hereditary breast-cancer risk. Lancet 2005, 365:1747–1749.

    Article  PubMed  Google Scholar 

  27. Cullinane CA, Lubinski J, Neuhausen SL, et al.:Effect of pregnancy as a risk factor for breast cancer in BRCA1/ BRCA2 mutation carriers. Int J Cancer 2005 Jun 28; [Epub ahead of print].

  28. Jernstrom H, Lubinski J, Lynch HT, et al.: Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2004, 96:1094–1098.

    Article  PubMed  CAS  Google Scholar 

  29. Narod SA, Dube MP, Klijn J, et al.: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002, 94:1773–1779.

    PubMed  CAS  Google Scholar 

  30. Milne RL, Knight JA, John EM, et al.: Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2005, 14:350–356. This study finds that oral contraceptives may protect against breast cancer in BRCA mutation carriers.

    Article  PubMed  CAS  Google Scholar 

  31. Ghadirian P, Lubinski J, Lynch H, et al.: Smoking and the risk of breast cancer among carriers of BRCA mutations. Int J Cancer 2004, 110:413–416.

    Article  PubMed  CAS  Google Scholar 

  32. Nkondjock A, Ghadirian P, Kotsopoulos J, et al.: Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer 2005 Jul 19; [Epub ahead of print].

  33. Narod SA, Offit K: Prevention and management of hereditary breast cancer. J Clin Oncol 2005, 23:1656–1663.

    Article  PubMed  Google Scholar 

  34. Foulkes WD, Stefansson IM, Chappuis PO, et al.: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003, 95:1482–1485. This study describes the association between BRCA1 mutation-associated breast cancer and the basal epithelial subtype, a finding that may explain the possibly inferior prognosis of BRCA1 mutation-associated breast cancer.

    PubMed  CAS  Google Scholar 

  35. Robson M, Levin D, Federici M, et al.: Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 1999, 91:2112–2117.

    Article  PubMed  CAS  Google Scholar 

  36. Haffty BG, Harrold E, Khan AJ, et al.: Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 2002, 359:1471–1477. This study describes the risks of ipsilateral breast tumor recurrence and contralateral breast cancer after breast-conserving therapy for BRCA mutation carriers with breast cancer.

    Article  PubMed  Google Scholar 

  37. Seynaeve C, Verhoog LC, van de Bosch LM, et al.: Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 2004, 40:1150–1158.

    Article  PubMed  CAS  Google Scholar 

  38. Robson ME, Chappuis PO, Satagopan J, et al.: A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004, 6:R8-R17.

    Article  PubMed  CAS  Google Scholar 

  39. Robson M, Svahn T, McCormick B, et al.: Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 2005, 103:44–51.

    Article  PubMed  Google Scholar 

  40. Metcalfe K, Lynch HT, Ghadirian P, et al.: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004, 22:2328–2335.

    Article  PubMed  CAS  Google Scholar 

  41. McDonnell SK, Schaid DJ, Myers JL, et al.: Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001, 19:3938–3943. This important article describes the efficacy of contralateral prophylactic mastectomy in affected women with BRCA mutations.

    PubMed  CAS  Google Scholar 

  42. Evans DG, Lalloo F, Hopwood P, et al.: Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. Eur J Surg Oncol 2005 Jul 6; [Epub ahead of print].

  43. Schwartz MD, Lerman C, Brogan B, et al.: Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev 2005, 14:1003–1007.

    Article  PubMed  CAS  Google Scholar 

  44. Narod SA, Brunet JS, Ghadirian P, et al.: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000, 356:1876–1881.

    Article  PubMed  CAS  Google Scholar 

  45. Weitzel JN, Robson M, Pasini B, et al.: A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev 2005, 14:1534–1538.

    Article  PubMed  CAS  Google Scholar 

  46. Kennedy RD, Quinn JE, Mullan PB, et al.: The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004, 96:1659–1668. This excellent article describes the cellular functions of BRCA1 and preclinical evidence suggesting differential chemosensitivity by BRCA mutation status.

    Article  PubMed  CAS  Google Scholar 

  47. Bryant HE, Schultz N, Thomas HD, et al.: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913–917.

    Article  PubMed  CAS  Google Scholar 

  48. Farmer H, McCabe N, Lord CJ, et al.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917–921.

    Article  PubMed  CAS  Google Scholar 

  49. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al.: Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002, 31:55–59. This important article describes a newly identified germline mutation that may contribute to hereditary breast cancer.

    Article  PubMed  CAS  Google Scholar 

  50. Offit K, Pierce H, Kirchhoff T, et al.: Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet 2003, 4:1.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Genetics and Breast Cancer Medicine Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, 10021, New York, NY, USA

    Mark E. Robson MD

Authors
  1. Karen Lisa Smith MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark E. Robson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark E. Robson MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, K.L., Robson, M.E. Update on hereditary breast cancer. Curr Oncol Rep 8, 14–21 (2006). https://doi.org/10.1007/s11912-006-0004-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-006-0004-x

Keywords

Search

Navigation